KALA - カラ・ファ―マシュ―ティカルズ （Kala Pharmaceuticals Inc.） カラ・ファ―マシュ―ティカルズKALAのチャート
KALAの企業情報
| symbol | KALA |
|---|---|
| 会社名 | Kala Pharmaceuticals Inc （カラ・ファ―マシュ―ティカルズ） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 カラ・ファーマスーティカルズ(Kala Pharmaceuticals Inc.)はナノ粒子ベースの粘膜浸透性粒子（MPP）技術による治療薬の開発と商品化に重点を置くバイオ医薬品会社である。同社の最初の焦点は眼疾患の治療にある。同社の製品候補には、KPI-121 1％、KPI-121 0.25％およびMPP rTKIプログラムが含まれる。同社はKPI-121 1％について2つの第III相臨床試験を完了する。KPI-121 0.25％はドライアイ疾患の徴候および症状の一時的軽減用製品候補である。KPI-121 1％は手術後の炎症および疼痛処置用の1日2回の製品候補である。MPP rTKIプログラムは毎月の間隔で患者の眼に直接注入する網膜疾患治療法である。 カラ・ファ―マシュ―ティカルズは米国のバイオ医薬品企業。眼科疾患を治療するナノ粒子ベ―ス「Mucus Penetraiting Particles」(MPP)技術を用いた医薬品の開発・商業化に従事する。ナノ粒子はサイズが選択可能で、粘液による薬物粒子の移動性を高める。眼科手術後の炎症、ドライアイや網膜疾患の治療に使われる。本社はマサチュ―セッツ州ウォルサム。 Kala is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative therapies for diseases of the eye. Kala has applied its AMPPLIFY® mucus-penetrating particle (MPP) Drug Delivery Technology to two ocular therapies, EYSUVIS™ (loteprednol etabonate ophthalmic suspension) 0.25% for the short-term (up to two weeks) treatment of signs and symptoms of dry eye disease and INVELTYS® (loteprednol etabonate ophthalmic suspension) 1% for the treatment of post-operative inflammation and pain following ocular surgery. The Company also has a pipeline of pre-clinical development programs targeted to address unmet medical needs, including both front and back of the eye diseases. |
| 本社所在地 | 100 Beaver Street Suite 201 Waltham MA 02453 USA |
| 代表者氏名 | Mark T. Iwicki Mark T. Iwicki |
| 代表者役職名 | Chairman of the Board President Chief Executive Officer 取締役会長兼最高経営責任者（CEO） |
| 電話番号 | +1 781-996-5252 |
| 設立年月日 | 39965 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 2017年 |
| 従業員数 | 37人 |
| url | www.kalarx.com |
| nasdaq_url | https://www.nasdaq.com/symbol/kala |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -45.82500 |
| 終値（lastsale） | 8.31 |
| 時価総額（marketcap） | 204481460.94 |
| 時価総額 | 時価総額（百万ドル） 306.72840 |
| 売上高 | 売上高（百万ドル） 0.00000 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 235.29040 |
| 当期純利益 | 当期純利益（百万ドル） -47.38200 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Kala Pharmaceuticals Inc revenues was not reported. Net loss increased 25% to $25.9M. Higher net loss reflects General and administrative - Balancing v increase from $2.4M to $9.9M (expense) Stock-Based Compensation increase from $697K to $2.8M (expense) Stock-Based Compensation increase from $392K to $1.4M (expense). |
KALAのテクニカル分析
KALAのニュース
Why Aclaris Therapeutics Shares Are Trading Lower By Around 55%? Here Are Other Stocks Moving In Monday''s Mid-Day Session 2023/03/06 18:25:46 Benzinga
Gainers Unicycive Therapeutics, Inc. (NASDAQ: UNCY ) shares surged 159% to $1.27 after the company announced a private placement of up to $130 million in gross proceeds to commercialize and launch Renazorb. BridgeBio Pharma, Inc. (NASDAQ: BBIO ) shares jumped 59.5% to $17.34 after the company announced positive data for its phase 2 study of Infigratinib in Achondroplasia. Avalon GloboCare Corp. (NASDAQ: ALBT ) shares gained 53.5% to $3.3330. Azul S.A. (NYSE: AZUL ) gained 45.3% to $6.05 after the company announced a deal to reduce the immediate cash it must expend for leased property. Kala Pharmaceuticals, Inc. (NASDAQ: KALA ) rose 28.3% to $21.49. HC Wainwright & Co. maintained Kala Pharmaceuticals with a Buy and raised the price target from $12 to $20.Kala Pharmaceuticals recently said Q4 adjusted EPS results were higher year over year. TCR2 Therapeutics Inc. (NASDAQ: TCRR ) gained 28% to $1.55 after the company and Adaptimmune announced a strategic combination to create a preeminent cell therapy company for solid tumors.
Is Kala Pharmaceuticals Inc. (NASDAQ:KALA) stock a better investment at this time? 2023/03/06 17:32:00 US Post News
Currently, Kala Pharmaceuticals Inc.’s (KALA) stock is trading at $21.50, marking a gain of 28.36% from last night’s close. At this price, the stock is -77.84% below its 52-week high of $97.00 and 506.59% above its 52-week low of $3.54. Based on the past 30-day period, the stock price is -3.27% below the high and […]
10 Short Squeeze Candidates: China Jo-Jo Drugstores, Expion360, MoonLake, Silvergate And More 2023/03/06 16:43:31 Benzinga
Potential short squeeze plays gained steam in 2021 and continued through 2022, with new traders looking for the next huge move. High short interest and a high cost to borrow are among the common traits that could lead to a short squeeze. Here’s a look at the top five short squeeze candidates this week based on the Fintel short squeeze leaderboard and some other stocks to watch that are moving up the list. Related Link: What Is A Short Squeeze? China Jo-Jo Drugstores (NASDAQ: CJJD ): The pharmaceutical retailer and distributor moves up two positions from last week’s leaderboard to top the week. Data shows 26.9% of the float short, compared to 10.7% last week. The cost to borrow is listed at 50.*%, up from last week’s 38.7%. The stock was also recently featured in Benzinga’s “Stock Whisper” Index thanks to increased interest in the name. Kala Pharmaceuticals (NASDAQ: KALA ): No stranger to the short squeeze leaderboard, Kala Pharmaceuticals moves up eight positions to rank second for the week.
Kennedy-Wilson, Radian Group, BridgeBio Pharma And Other Big Stocks Moving Higher On Monday 2023/03/06 15:26:38 Benzinga
U.S. stocks traded higher, with the Dow Jones gaining around 100 points on Monday. Here are some big stocks recording gains in today’s session. BridgeBio Pharma, Inc. (NASDAQ: BBIO ) shares surged 59.5% to $17.34 after the company announced positive data for its phase 2 study of Infigratinib in Achondroplasia. Azul S.A. (NYSE: AZUL ) gained 45.3% to $6.05 after the company announced a deal to reduce the immediate cash it must expend for leased property. Kala Pharmaceuticals, Inc. (NASDAQ: KALA ) gained 28.3% to $21.49. HC Wainwright & Co. maintained Kala Pharmaceuticals with a Buy and raised the price target from $12 to $20.Kala Pharmaceuticals recently said Q4 adjusted EPS … Full story available on Benzinga.com
Thinking about buying stock in BridgeBio Pharma, Kala Pharmaceuticals, Azul, Unicycive Therapeutics, or Ciena Corp? 2023/03/06 13:30:00 Benzinga
NEW YORK , March 6, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for BBIO, KALA, AZUL, UNCY, and CIEN. … Full story available on Benzinga.com
Kala Pharmaceuticals Inc. (NASDAQ:KALA) 90.35% Above Its 52-Week Low, How Long Will It Keep Rising? 2023/01/06 14:30:00 Marketing Sentinel
In last trading session, Kala Pharmaceuticals Inc. (NASDAQ:KALA) saw 3.68 million shares changing hands with its beta currently measuring -0.55. Company’s recent per share price level of $36.67 trading at -$5.42 or -12.88% at ring of the bell on the day assigns it a market valuation of $36.30M. That closing price of KALA’s stock is … Kala Pharmaceuticals Inc. (NASDAQ:KALA) 90.35% Above Its 52-Week Low, How Long Will It Keep Rising? Read More »
ReShape, Scilex top healthcare gainers; Palisade, Kala among losers 2023/01/03 15:05:29 Seeking Alpha
ReShape Lifesciences (RSLS) +138%. Scilex (SCLX) +41%. Palisade Bio (PALI) -16%. Kala Pharmaceuticals (KALA) -15%.
Kala Pharmaceuticals stock up 750% in 3 days after upbeat FDA news on PCED treatment 2022/12/30 17:02:00 MarketWatch
Shares of Kala Pharmaceuticals Inc. have rocketed higher in for three-straight sessions, toward a more-than 8-fold gain, since the biopharmaceutical company…
Worth Watching Stocks: Kala Pharmaceuticals, Inc. (NASDAQ:KALA), AT&T Inc. (NYSE:T) 2022/12/30 16:32:59 Stock Equity
Current Technical and Performance analysis of the following stocks Kala Pharmaceuticals, Inc. (KALA) with the stream of 26.05% also noticed, India AT&T Inc. (T) showing a change of -0.14% in … The post Worth Watching Stocks: Kala Pharmaceuticals, Inc. (NASDAQ:KALA), AT&T Inc. (NYSE:T) appeared first on Stocks Equity .
Friday’s Top Analyst Upgrades and Downgrades: AMC, CNH, Opendoor, Tesla and More 2022/12/30 13:34:50 24/7 Wall street
Friday''s top analyst upgrades and downgrades included AMC Entertainment, CNH Industrial, Kala Pharmaceuticals, Opendoor Technologies, Tesla and TG Therapeutics.
Alluring stocks: Genius Brands International, Inc. (NASDAQ:GNUS 0.32%), Kala Pharmaceuticals, Inc. (NASDAQ:KALA -3.09%) 2022/08/02 23:41:11 Stock Equity
There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well have a look on, SMA50 … The post Alluring stocks: Genius Brands International, Inc. (NASDAQ:GNUS 0.32%), Kala Pharmaceuticals, Inc. (NASDAQ:KALA -3.09%) appeared first on Stocks Equity .
Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) 2022/07/22 20:01:00 GlobeNewswire
ARLINGTON, Mass., July 22, 2022 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), today announced that the Company granted non-statutory stock options to a new employee as an inducement award outside the Company’s 2017 Equity Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4).
Kala Pharmaceuticals Inc. (NASDAQ: KALA) Jumps 4.89%, Turning Investors Away 2022/06/06 15:30:00 Stocks Register
Kala Pharmaceuticals Inc. (NASDAQ:KALA) traded at $0.38 at close of the session on Friday, 06/03/22, made an upward move of 4.89% on its previous day’s price. Looking at the stock we see that its previous close was $0.36 and the beta (5Y monthly) reads 0.62 with the day’s price range being $0.355 – $0.3951. In … Kala Pharmaceuticals Inc. (NASDAQ: KALA) Jumps 4.89%, Turning Investors Away Read More »
Kala Pharmaceuticals, Inc. Expected to Post Earnings of -$0.38 Per Share 2022/06/06 00:29:09 Business Mag
Wall Street analysts expect Kala Pharmaceuticals, Inc. to report earnings of per share for the current fiscal quarter, Zacks Investment Research reports. Six analysts have…
Kala Pharmaceuticals to Present at Jefferies Healthcare Conference 2022/06/02 12:00:00 GlobeNewswire
ARLINGTON, Mass., June 02, 2022 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that it will present at the Jefferies Healthcare Conference in New York, NY. Members from the management team are scheduled to participate in a fireside chat on Thursday, June 9, 2022 at 10:30 a.m. ET. Management will also be available for one-on-one meetings on Wednesday, June 8, 2022 and Thursday, June 9, 2022.